United Pharm (033270) - Total Assets
Based on the latest financial reports, United Pharm (033270) holds total assets worth ₩519.49 Billion KRW (≈ $352.05 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of United Pharm for net asset value and shareholders' equity analysis.
United Pharm - Total Assets Trend (2011–2025)
This chart illustrates how United Pharm's total assets have evolved over time, based on quarterly financial data.
United Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
United Pharm's total assets of ₩519.49 Billion consist of 51.7% current assets and 48.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.8% |
| Accounts Receivable | ₩38.50 Billion | 7.4% |
| Inventory | ₩64.26 Billion | 12.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩10.55 Billion | 2.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how United Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is United Pharm worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: United Pharm's current assets represent 51.7% of total assets in 2025, an increase from 51.7% in 2011.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2025, down from 10.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 12.4% of total assets.
United Pharm Competitors by Total Assets
Key competitors of United Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
United Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.63 | 5.08 | 2.96 |
| Quick Ratio | 4.28 | 3.79 | 2.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩220.93 Billion | ₩196.56 Billion | ₩128.97 Billion |
United Pharm - Advanced Valuation Insights
This section examines the relationship between United Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | ₩519.49 Billion |
| Market Capitalization | $197.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values United Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: United Pharm's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for United Pharm (2011–2025)
The table below shows the annual total assets of United Pharm from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩519.49 Billion ≈ $352.05 Million |
+9.61% |
| 2024-12-31 | ₩473.93 Billion ≈ $321.17 Million |
+1.08% |
| 2023-12-31 | ₩468.86 Billion ≈ $317.74 Million |
+12.20% |
| 2022-12-31 | ₩417.89 Billion ≈ $283.20 Million |
+9.96% |
| 2021-12-31 | ₩380.03 Billion ≈ $257.54 Million |
+7.53% |
| 2020-12-31 | ₩353.43 Billion ≈ $239.52 Million |
+6.70% |
| 2019-12-31 | ₩331.24 Billion ≈ $224.48 Million |
+9.70% |
| 2018-12-31 | ₩301.95 Billion ≈ $204.63 Million |
+13.60% |
| 2017-12-31 | ₩265.80 Billion ≈ $180.13 Million |
+13.48% |
| 2016-12-31 | ₩234.22 Billion ≈ $158.73 Million |
+7.89% |
| 2014-12-31 | ₩217.10 Billion ≈ $147.13 Million |
+12.17% |
| 2013-12-31 | ₩193.54 Billion ≈ $131.16 Million |
+3.18% |
| 2012-12-31 | ₩187.58 Billion ≈ $127.12 Million |
+10.28% |
| 2011-12-31 | ₩170.09 Billion ≈ $115.26 Million |
-- |
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more